No correlation between time‐linked plasma and CSF Aβ levels
Abstract
Plasma beta-amyloid protein (Abeta) isoforms are considered potential biomarkers for Alzheimer's disease (AD) and dementia. The relation between plasma and cerebrospinal fluid (CSF) levels of Abeta isoforms remains unclear. In order to identify possible correlations between Abeta levels in plasma and CSF we determined Abeta levels in time-linked plasma and CSF samples. Abeta concentrations in plasma (Abeta(1-42) and Abeta(N-42)) and CSF (Abeta(1-42)) samples from 49 AD patients, 47 non-Alzheimer's disease dementia (NONAD) patients, 39 MCI patients and 29 controls were determined using a multi-parameter fluorimetric bead-based immunoassay using xMAP((R)) technology (for plasma) and a conventional single-parameter ELISA (for CSF). Plasma Abeta(1-42) concentrations did not correlate with CSF Abeta(1-42) concentrations in the total study population, or in the different diagnostic groups. No correlations between plasma Abeta(N-42) and CSF Abeta(1-42) levels were found either. The CSF/serum albumin index did not show any significant differences between AD, NONAD, MCI and controls. These results suggest that the Abeta levels in plasma are independent of the Abeta levels in CSF both in dementia and controls. The fact that CSF and plasma Abeta do not correlate in patients as well as controls and no significant differences in plasma Abeta(1-42) or Abeta(N-42) between patients and controls can be detected hampers the diagnostic utility of the plasma Abeta levels as biomarkers for dement…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Previous studies have evaluated protein correlations between plasma and CSF biomarkers of AD.
“Previous studies have evaluated protein correlations between plasma and CSF biomarkers of AD. 37 , 38 , 39 , 40 , 41 , 42 , 43”
From A genetic and proteomic comparison of key AD biomarkers across tissues (2024) · cites this paper as [39]
Some previous studies indicate a poor correlation between plasma and CSF biomarkers, and some indicate a strong correlation.
“Some of these studies indicate a poor correlation between plasma and CSF biomarkers, 39 and some indicate a strong correlation, 41”
From A genetic and proteomic comparison of key AD biomarkers across tissues (2024) · cites this paper as [39]
Cites
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Blood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress
Keshavan, A., Heslegrave, A., Zetterberg, H., & Schott, J. M. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0241-0 · Cited by 34 · see citing works
A genetic and proteomic comparison of key AD biomarkers across tissues
Marsh, T. W., Western, D., Timsina, J., Gorijala, P., Yang, C., Pastor, P., Liu, M., Morris, J. C., Bateman, R. J., Schindler, S. E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14139 · Cited by 6 · see citing works
- Authors
- Le Bastard, N., Aerts, L., Leurs, J., Blomme, W., De Deyn, P. P., & Engelborghs, S.
- Affiliations
- University of Antwerp (BE)
- Venue
- Neurochemistry International
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 55
- Issue
- 8
- Pages
- 820-825
- ISSN
- 0197-0186 (ISSN-L)
- OpenAlex
- W2037239828
- Cited by
- 59
- References
- 1
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 6 · 2019: 1 · 2018: 4 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 3 · 2013: 5 · 2012: 5
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurochemistry International (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- amyloid-beta, cerebrospinal fluid amyloid, Alzheimer's disease, dementia, mild cognitive impairment, biomarkers, amyloid-beta 42
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Brain Chemistry, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Neurochemistry, Peptide Fragments, Predictive Value of Tests, Sensitivity and Specificity, Time Factors, Biomarkers, Amyloid beta-Peptides, Fluorescence Polarization Immunoassay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review